LabMed
Mantle Cell Lymphoma
-
At a Glance
-
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
-
Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?
-
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
At a Glance
Mantle cell lymphoma is a small B-cell lymphoma that is clinically more aggressive than other small B-cell non-Hodgkin lymphomas. It commonly presents at a higher stage, including bone marrow and peripheral blood involvement. It is a disease of adults and is more common in men.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
Mantle cell lymphoma is usually diagnosed by biopsy of lymph node or bone marrow. Other commonly affected sites are the gastrointestinal (GI) tract (multiple lymphomatous polyposis) and Waldeyer's ring. Many patients also have circulating lymphoma cells in their peripheral blood. Mantle cell lymphoma is classically a diffuse infiltrate of monotonous small hyperchromatic lymphocytes. Immunohistochemical staining showing CD20+ small lymphocytes positive for CD5 and cyclin D1 (also called BCL-1) is diagnostic of mantle cell lymphoma.
Flow cytometry is very helpful in identifying the monoclonal B-cell population. The characteristic immunophenotype of the monoclonal B-cells of mantle cell lymphoma is CD45+, CD19+, CD20+, CD5+, CD10- CD23-, and FMC7+. Cytogenetic karyotype and fluorescence in situ hybridization (FISH) studies can be very helpful. The presence of t(11;14) (q13;q32) between IgH and CCND1 is diagnostic of this lymphoma and is present in nearly every case. Molecular polymerase chain reaction (PCR) studies to look for IgH gene rearrangement are usually not performed but would show a clonal B-cell population.
Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?
Mantle cell lymphoma can sometimes have histologic and immunophenotypic overlap with chronic lymphocytic leukemia/small lymphocytic lymphoma or other small B-cell lymphomas. In any case that is not straightforward, staining for cycling D1 and cytogenetic FISH for t(11; 14) can be performed to look for the characteristic positive results in mantle cell lymphoma. Mantle cell lymphoma can have some morphologic variants that may make diagnosis challenging, such as blastoid, pleomorphic, small cell, or marginal zone-like variants.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
Patients are usually referred to an oncologist after their initial diagnosis for full clinical staging, including lab work, radiology imaging, and a bone marrow biopsy. Because of the more aggressive nature of this lymphoma, it is often treated more intensely than other lymphomas.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |